III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

Respiratory illnesses, including RSV, flu, and COVID-19, are surging across the US, particularly impacting young children in ...